JNJ vs PFE: Johnson & Johnson vs Pfizer Inc. Historical Returns & Investment Comparison
This JNJ vs PFE comparison analyzes the historical stock performance of Johnson & Johnson and Pfizer Inc. side-by-side. Using real, adjusted market data, this tool shows how identical investments in both stocks would have performed over time—highlighting differences in returns, volatility, and consistency across market cycles.
Use the interactive calculator below to adjust the investment amount and time period, visualizing how Johnson & Johnson and Pfizer Inc. have historically performed against each other.
Compare Stock Performance
Select two stocks and an investment amount to see how they compare over time.
Compare any two stocks to see which performed better historically
Performance Summary
$10,000 invested from 1986 to 2025 (40 years)
Head-to-Head Record
Over the 40-year comparison period, Johnson & Johnson outperformed Pfizer Inc. in 24 years, while Pfizer Inc. outperformed Johnson & Johnson in 16 years.
JNJ - Johnson & Johnson
PFE - Pfizer Inc.
Overall Winner: JNJ with an average annual return of 14.96% (vs 13.39% for PFE)
Understanding JNJ vs PFE Performance
When comparing Johnson & Johnson and Pfizer Inc., investors should consider multiple factors beyond just total returns. Volatility, consistency of growth, dividend payments, and sector-specific risks all play crucial roles in determining which stock might be better suited for your investment strategy and risk tolerance.
Historical performance data shows how each stock responded to market downturns, economic expansions, and company-specific events. While past performance doesn't guarantee future results, understanding these patterns can help inform investment decisions and portfolio allocation strategies.
Cumulative Growth Comparison
A $10,000 investment in Johnson & Johnson grew to $1,652,673, compared to $371,677 for Pfizer Inc. over the same period.
Year-by-Year Comparison
| Year | JNJ Return | JNJ Cumulative | PFE Return | PFE Cumulative | Difference | Winner |
|---|---|---|---|---|---|---|
| 1986 (Start) | - | $10,000.00 | - | $10,000.00 | - | Initial Investment |
| 1987 | +29.27% | $12,926.97 | +25.54% | $12,553.78 | +3.73% (JNJ) | JNJ |
| 1988 | +13.25% | $14,639.88 | -22.64% | $9,712.13 | +35.89% (JNJ) | JNJ |
| 1989 | +11.66% | $16,346.85 | +23.97% | $12,040.07 | -12.31% (PFE) | PFE |
| 1990 | +45.20% | $23,735.26 | +24.70% | $15,014.42 | +20.49% (JNJ) | JNJ |
| 1991 | +22.37% | $29,046.02 | +17.78% | $17,683.77 | +4.60% (JNJ) | JNJ |
| 1992 | +66.37% | $48,324.54 | +114.43% | $37,919.27 | -48.06% (PFE) | PFE |
| 1993 | -8.39% | $44,270.64 | -11.96% | $33,383.94 | +3.57% (JNJ) | JNJ |
| 1994 | -7.13% | $41,115.13 | -2.11% | $32,678.70 | -5.02% (PFE) | PFE |
| 1995 | +24.02% | $50,988.97 | +17.01% | $38,236.65 | +7.01% (JNJ) | JNJ |
| 1996 | +59.85% | $81,507.55 | +69.44% | $64,787.19 | -9.58% (PFE) | PFE |
| 1997 | +19.86% | $97,691.64 | +35.60% | $87,852.84 | -15.75% (PFE) | PFE |
| 1998 | +34.29% | $131,193.40 | +84.42% | $162,017.05 | -50.13% (PFE) | PFE |
| 1999 | +30.59% | $171,327.42 | +66.41% | $269,606.76 | -35.81% (PFE) | PFE |
| 2000 | +14.09% | $195,465.49 | -20.54% | $214,217.10 | +34.63% (JNJ) | JNJ |
| 2001 | +15.56% | $225,888.32 | +45.58% | $311,857.42 | -30.02% (PFE) | PFE |
| 2002 | +17.42% | $265,249.10 | -12.71% | $272,214.72 | +30.14% (JNJ) | JNJ |
| 2003 | -7.25% | $246,014.23 | -22.25% | $211,634.21 | +15.00% (JNJ) | JNJ |
| 2004 | -4.94% | $233,854.96 | +14.16% | $241,608.19 | -19.11% (PFE) | PFE |
| 2005 | +25.17% | $292,712.05 | -22.78% | $186,563.62 | +47.95% (JNJ) | JNJ |
| 2006 | -2.56% | $285,212.68 | -9.14% | $169,507.12 | +6.58% (JNJ) | JNJ |
| 2007 | +9.64% | $312,716.94 | +13.03% | $191,592.85 | -3.39% (PFE) | PFE |
| 2008 | +3.02% | $322,157.66 | -9.50% | $173,394.78 | +12.52% (JNJ) | JNJ |
| 2009 | -6.61% | $300,859.26 | -17.61% | $142,859.34 | +11.00% (JNJ) | JNJ |
| 2010 | +9.76% | $330,237.14 | +4.88% | $149,836.13 | +4.88% (JNJ) | JNJ |
| 2011 | -1.00% | $326,928.49 | -3.61% | $144,432.51 | +2.60% (JNJ) | JNJ |
| 2012 | +8.19% | $353,712.59 | +27.55% | $184,217.58 | -19.35% (PFE) | PFE |
| 2013 | +10.34% | $390,295.72 | +18.62% | $218,512.25 | -8.27% (PFE) | PFE |
| 2014 | +33.22% | $519,944.75 | +22.16% | $266,941.83 | +11.05% (JNJ) | JNJ |
| 2015 | +18.06% | $613,842.47 | +5.86% | $282,595.33 | +12.20% (JNJ) | JNJ |
| 2016 | +1.19% | $621,150.82 | +6.47% | $300,886.88 | -5.28% (PFE) | PFE |
| 2017 | +17.90% | $732,338.51 | +5.50% | $317,445.94 | +12.40% (JNJ) | JNJ |
| 2018 | +23.75% | $906,258.36 | +14.08% | $362,127.92 | +9.67% (JNJ) | JNJ |
| 2019 | -4.80% | $862,779.53 | +24.07% | $449,275.30 | -28.86% (PFE) | PFE |
| 2020 | +17.40% | $1,012,926.30 | -6.05% | $422,107.84 | +23.45% (JNJ) | JNJ |
| 2021 | +10.75% | $1,121,793.39 | +3.17% | $435,509.08 | +7.57% (JNJ) | JNJ |
| 2022 | +12.06% | $1,257,134.49 | +66.70% | $725,972.09 | -54.63% (PFE) | PFE |
| 2023 | +5.68% | $1,328,596.83 | -6.61% | $677,967.98 | +12.30% (JNJ) | JNJ |
| 2024 | -9.37% | $1,204,127.55 | -41.29% | $398,055.16 | +31.92% (JNJ) | JNJ |
| 2025 | -6.73% | $1,123,048.36 | -5.31% | $376,923.37 | -1.42% (PFE) | PFE |
| 2026 | +47.16% | $1,652,673.36 | -1.39% | $371,676.95 | +48.55% (JNJ) | JNJ |
Annual returns include dividends and stock splits. Cumulative values show growth of $10,000 invested from the first year. Positive difference means JNJ outperformed PFE that year.
Company Profiles
Johnson & Johnson
JNJ
Pharmaceutical and consumer healthcare
Pfizer Inc.
PFE
Pfizer is a world-leading biopharmaceutical company. It discovers, develops, manufactures, and markets healthcare products, including medicines and vaccines.
Key Innovations
- ✓Comirnaty (COVID-19 vaccine)
- ✓Paxlovid (COVID-19 antiviral)
- ✓Lipitor (historically highest selling drug)
Business Segments
- Primary CareInternal medicine, vaccines, and COVID-19 products.
- Specialty CareInflammation, immunology, rare diseases, and hospital products.
- OncologyCancer treatments (includes Seagen acquisition).
How This Comparison Works
Our stock comparison tool uses adjusted closing prices to calculate year-by-year returns for both stocks. This ensures an apples-to-apples comparison that accounts for:
- ✓Dividends: All dividend payments are reinvested
- ✓Stock splits: Historical prices are adjusted for all splits
- ✓Head-to-head record: Shows which stock outperformed each year
- ✓Statistical analysis: Average returns, best/worst years, and win rates
Share This Comparison
People also compared
Important Disclaimer
This comparison tool is for educational and informational purposes only and does not constitute financial, investment, or trading advice. Past performance is not indicative of future results. Historical returns include dividends and stock splits but do not account for taxes, fees, inflation, or individual circumstances. Stock market investments carry risk, including the potential loss of principal. Always consult with a qualified financial advisor before making investment decisions. The data presented is based on historical market data and may contain inaccuracies or delays.